Have you been eager to see how The Charles Schwab Corporation (SCHW - Free Report) performed in Q1 in comparison with the market expectations? Let’s quickly scan through the key facts from this San Francisco-based brokerage company’s earnings release this morning:
An Earnings Beat
Schwab came out with earnings per share of 55 cents, beating the Zacks Consensus Estimate of 54 cents.
Results benefited from improved revenues.
How Was the Estimate Revision Trend?
You should note that the earnings estimate revisions for Schwab depicted an optimistic stance prior to the earnings release. The Zacks Consensus Estimate has moved 1.9% upward over the last seven days.
Also, Schwab has delivered positive surprises in three of the prior four trailing quarters. Overall, the company has a positive earnings surprise of 3.8% in the trailing four quarters.
Schwab posted net revenues of $2.40 billion, which surpassed the Zacks Consensus Estimate of $2.37 billion. Also, it compared favorably with the year-ago number of $2.08 billion.
- A steady focus on serving investor needs has helped Schwab’s business grow to $3.31 trillion in client assets as of Mar 31, 2018
- Increase in average interest-earning assets by 10% to $238.5 billion at the end of the reported quarter
- Fee waivers were nil in the reported quarter.
What Zacks Rank Says
The estimate revisions that we discussed earlier have driven a Zacks Rank #3 (Hold) for Schwab. However, since the latest earnings performance is yet to be reflected in the estimate revisions, the rank is subject to change. While things apparently look favorable, it all depends on what sense the just-released report makes to the analysts.
(You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.)
How the Market Reacted So Far
Following the earnings release, Schwab shares were up nearly 1.4% in the pre-trading session. This is in contrast with what the stock witnessed in the prior-day’s session. Clearly, the initial reaction shows that the investors have considered the results in their favor. However, the full-session’s price movement may indicate a different picture.
Check back later for our full write up on this Schwab earnings report!
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>